Complex Regional Pain Syndrome

What it is

Complex regional pain syndrome (CRPS), formerly called reflex sympathetic dystrophy (RSD) for Type I and causalgia for Type II, is a chronic neuropathic pain disorder characterized by:

• Pain disproportionate to the inciting event: typically severe, burning, or shooting pain that exceeds what would be expected from the original injury.
• Sensory features: allodynia (pain from non-painful stimuli like light touch) and hyperalgesia (heightened pain response).
• Autonomic dysregulation: changes in skin temperature, color, sweating, and edema.
• Motor and trophic changes: weakness, tremor, dystonia, and changes in hair, nail, and skin texture.

CRPS Type I follows soft-tissue injury, fracture, or surgery without identifiable nerve injury. CRPS Type II follows confirmed peripheral nerve injury. Diagnosis is clinical, based on the Budapest Criteria (International Association for the Study of Pain), which require disproportionate pain plus signs and symptoms across multiple of four categories (sensory, vasomotor, sudomotor/edema, motor/trophic).

CRPS most commonly affects an upper or lower extremity following injury — Colles' fracture, ankle sprain or fracture, carpal tunnel release, knee surgery, and shoulder injuries are common precipitants. Prevalence is estimated at 5-26 cases per 100,000 person-years; women are affected approximately three times more often than men. Many patients experience substantial functional and occupational disability; some develop spread to other limbs over time.

Cannabis and cannabis-derived therapies

Direct trial evidence for cannabis in CRPS specifically is limited. No large randomized controlled trial of cannabis or cannabinoids has been completed in a CRPS population.

Indirect evidence is substantial. The 2017 NASEM consensus report rated chronic pain in adults at its highest evidence tier (substantial/conclusive), with the strongest underlying trial evidence in neuropathic pain conditions:

• HIV-associated neuropathy: multiple placebo-controlled trials of inhaled cannabis showing significant pain reduction.
• Diabetic peripheral neuropathy: controlled trials of inhaled cannabis and nabiximols showing pain reduction.
• Chemotherapy-induced peripheral neuropathy: trials of nabiximols and oral cannabinoids showing benefit.
• Post-herpetic neuralgia: several trials supporting cannabinoid analgesia.
• Central neuropathic pain (MS, spinal cord injury): strong trial evidence for nabiximols.

CRPS is mechanistically a chronic neuropathic pain syndrome with mixed peripheral and central components. The neuropathic-pain evidence base supports a plausible expectation of cannabinoid benefit, though the CRPS-specific randomized trials needed to establish efficacy in this population do not yet exist.

Symptom-specific picture

• Burning and shooting neuropathic pain: indirect support from the NASEM chronic-pain evidence base, particularly for the neuropathic-pain subgroup.
• Allodynia and hyperalgesia: some patient-reported benefit; mechanism plausibly involves CB1-mediated reduction of peripheral and central sensitization.
• Sleep disturbance: common in CRPS due to chronic pain; cannabis effect on sleep is consistent with the broader chronic-pain literature.
• Autonomic features (temperature, color, sweating changes): no specific cannabinoid evidence base.
• Motor and trophic features (dystonia, weakness, skin changes): limited specific evidence; motor outcomes are more responsive to rehabilitation than to pharmacotherapy.
• Anxiety and depression: common in chronic CRPS; cannabis effects on these comorbidities are variable.

Endocannabinoid pharmacology in neuropathic pain

The endocannabinoid system is densely expressed in pain-processing pathways:

• Peripheral nerves and dorsal root ganglion: CB1 and CB2 receptors are present and modulate nociceptive signaling.
• Spinal cord dorsal horn: CB1 receptors modulate primary afferent transmission and descending pain control.
• Brain pain-processing regions: periaqueductal gray, rostral ventromedial medulla, anterior cingulate cortex, and insula all express CB1 receptors.
• Immune cells: CB2 receptors on microglia and peripheral immune cells modulate neuroinflammation, which is implicated in CRPS pathophysiology.

CRPS pathophysiology involves peripheral sensitization, central sensitization, neurogenic inflammation, and autonomic dysregulation — all processes in which the endocannabinoid system has documented modulatory activity. This is a plausible mechanistic basis for cannabinoid benefit, though the CRPS-specific trial data needed to establish clinical efficacy do not yet exist.

Standard CRPS therapy

Cannabis is symptomatic only and does not replace evidence-based CRPS management. The strongest long-term outcome evidence is for early, intensive rehabilitation:

• Physical and occupational therapy: the foundation of treatment. Graded motor imagery, mirror therapy, desensitization, and progressive functional rehabilitation have the strongest long-term outcome evidence. Functional restoration is the primary outcome goal, not just pain reduction.
• Neuropathic pain pharmacotherapy: gabapentin, pregabalin, amitriptyline, duloxetine, nortriptyline. Adequate-dose trials are essential.
• Topical agents: capsaicin, lidocaine, ketamine-amitriptyline compounds.
• Sympathetic nerve blocks: stellate ganglion blocks (upper extremity) or lumbar sympathetic blocks (lower extremity); diagnostic and sometimes therapeutic.
• Bisphosphonates: alendronate, neridronate; evidence for early CRPS to reduce bone-resorption-mediated pain and prevent osteoporosis from disuse.
• Spinal cord stimulation and dorsal root ganglion stimulation: for refractory cases; significant trial evidence for SCS in CRPS.
• Intravenous ketamine: subanesthetic infusions for refractory CRPS in tertiary pain programs.
• Psychological support: cognitive-behavioral therapy and pain psychology; chronic CRPS frequently coexists with depression, anxiety, and PTSD.

Early intervention is associated with substantially better outcomes than delayed treatment. Patients with CRPS who substitute cannabis for early rehabilitation may experience worsened long-term function.

Drug interactions

• Gabapentin and pregabalin: additive CNS depression, dizziness, and cognitive effects.
• Tricyclic antidepressants (amitriptyline, nortriptyline): additive sedation, anticholinergic effects, and orthostatic hypotension; CBD CYP2D6 inhibition can affect TCA levels.
• SNRIs (duloxetine): additive serotonergic and noradrenergic effects; CBD CYP1A2 and CYP2D6 effects modest.
• Opioids: additive CNS depression. Some CRPS patients use cannabis to reduce opioid requirement; the trade-offs include reduced opioid burden but unpredictable cannabis effect on acute pain.
• Bisphosphonates: no major direct interaction.
• Local anesthetics (for sympathetic blocks): cannabis combined with intrathecal or epidural anesthetic procedures requires anesthesia disclosure; additive CNS depression and altered hemodynamics may be relevant.
• Ketamine infusions: additive psychotomimetic effects; cannabis use should be coordinated with the infusion team.

Population considerations

• Pediatric and adolescent CRPS: pediatric CRPS often responds to intensive multidisciplinary rehabilitation. Cannabis is not first-line in this population; adolescent-onset chronic cannabis use carries elevated risk. Where pediatric medical cannabis is pursued for CRPS, high-CBD, low-THC formulations and pediatric-pain-team coordination are essential.
• Pregnancy and breastfeeding: cannabis is contraindicated. CRPS pharmacotherapy options in pregnancy are limited; multidisciplinary management is essential.
• Patients with co-occurring PTSD or anxiety: common in chronic CRPS, particularly after traumatic injury. Cannabis effects on these comorbidities are variable; coordination with mental health providers is appropriate.
• Workers' compensation patients: CRPS commonly arises from workplace injury, and many patients are in active workers' compensation claims. Workers' comp insurers vary widely in their coverage of medical cannabis; some states require employer coverage by statute, others permit denial. Patients should verify reimbursement before initiating cannabis under a comp claim.

State qualifying status overview

CRPS is explicitly listed as a qualifying condition in approximately a dozen state medical cannabis programs, including New Mexico, Minnesota, Illinois, Pennsylvania, Connecticut, New Hampshire, Maine, Louisiana, and Mississippi. Many additional states cover CRPS indirectly through chronic-pain, severe pain, intractable pain, or neuropathic pain qualifiers (Arkansas, Hawaii, Maryland, New York, Florida, Ohio). Discretionary-listing states (California, Oklahoma, Washington DC, Virginia, Massachusetts, Maryland, Rhode Island, Connecticut) allow physician-added certification.

Because CRPS has a well-documented chronic-pain phenotype, it is one of the conditions most likely to be covered by broad chronic-pain qualifiers in states that do not enumerate it specifically. The per-state matrix on mmjnow tracks current qualifying status for each medical-legal state.

Federal employment and clearance considerations

CRPS frequently develops after work-related injury, surgery, or trauma — populations that include federal employees, military service members, federal contractors, and CDL holders. State medical cannabis use does not create federal protection:

• Federal civilian employees: drug-free workplace rules apply.
• Security clearance holders: SEAD 4 treats current cannabis use as a clearance concern regardless of state legality, with no medical exception.
• Federal contractors: drug-free workplace requirements typically extend to state-legal cannabis.
• CDL holders: DOT testing prohibits cannabis use; positive test is disqualifying.
• Active-duty military: UCMJ Article 112a prohibits cannabis use regardless of state law.

Patients in these populations should consider whether alternative neuropathic-pain therapies (gabapentinoids, duloxetine, topicals, spinal cord stimulation) can provide adequate pain control without federal employment exposure.

Practical guidance

Cannabis use in CRPS should be adjunctive to early, intensive physical and occupational therapy and standard neuropathic-pain pharmacotherapy. Patients should not substitute cannabis for rehabilitation — functional restoration has the strongest long-term outcome evidence. Lower-THC, higher-CBD formulations are often preferred where the goal is pain reduction with minimal cognitive interference (which can compromise rehabilitation participation). Cannabis use should be disclosed to all prescribers and to the rehabilitation team, particularly before sympathetic block procedures, ketamine infusions, or surgical interventions. Driving or operating heavy equipment while acutely impaired is contraindicated.

Related conditions

CRPS overlaps clinically with chronic-pain, peripheral-neuropathy, spinal-cord-injury (in cases of post-surgical CRPS following spinal procedures), and (in chronic refractory cases) ptsd. The mmjnow library covers each as a separate condition with overlapping cannabinoid-evidence considerations.

Last reviewed 2026-05-18. This is informational only — not medical or legal advice.